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Abstract: Immune escape is a fundamental trait of cancer in which the Th1-type cytokine interferon-γ (IFN-γ) seems to play a key role. 
Among other tumoricidal biochemical pathways, IFN-γ induces the tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) 
in a variety of cells including macrophages, dendritic cells (DCs) and tumor cells. IDO activity has been shown to reflect the extent and 
the course in a plethora of malignancies including prostate, colorectal, pancreatic, cervical, endometrial, gastric, lung, bladder, ovar-
ian, esophageal and renal cell carcinomas, glioblastomas, mesotheliomas, and melanomas. Furthermore IDO activity during malignant 
tumor diseases seems to be part of the tumoricidal immune defense strategy, which in the long run is detrimental to the host, when 
tryptophan deprivation and production of pro-apoptotic tryptophan catabolites counteract T-cell responsiveness.
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Introduction
In  vitro,  Th1-type  cytokine  interferon-γ  (IFN-γ) 
induces  the  tryptophan-degrading  enzyme  indole-
amine  2,3-dioxygenase  (IDO)  in  monocyte-derived 
macrophages, dendritic cells and in a variety of other 
cell types including tumor cells. In vivo, accelerated 
tryptophan degradation can be detected in body fluids 
by measurements of kynurenine and tryptophan con-
centrations. Calculating the kynurenine to tryptophan 
ratio (kyn/trp) serves as an estimate of IDO functional 
activity. A large proportion of patients with a variety 
of disorders like viral or bacterial infections, autoim-
mune syndromes or during allograft rejection presents 
with increased kyn/trp in serum/plasma or cerebrospi-
nal fluid. Tryptophan degradation in these individuals 
reflects the extent, activity and the course of disease. 
In patients with malignant tumors, tryptophan deg-
radation parallels disease progression, loss of immu-
nocompetence and the development of cachexia and 
anemia. In addition, higher kyn/trp and lower trypto-
phan concentrations predict shorter overall survival.
The rate of tryptophan degradation in malignant cell 
lines is usually low but can be significantly enhanced by 
pro-inflammatory stimuli such as IFN-γ. Data suggest 
that tryptophan degradation in patients with cancer pre-
dominantly relates to enhanced IDO activity, which is 
stimulated during Th1-type immune response. This con-
clusion is further supported by the observation that kyn/
trp in humans usually correlates closely with neopterin 
concentrations, which is released by human monocyte-
derived macrophages and DCs particularly upon stim-
ulation with IFN-γ, but not by stimulated tumor cells 
themselves. Degradation of essential amino acid tryp-
tophan represents an effective anti-proliferative strat-
egy, which is established during immune response. It 
is directed to stop malignant proliferation as is to halt 
growth of pathogens in infected cells.
In 1996 we demonstrated accelerated tryptophan 
degradation correlating to neopterin levels in normal 
human pregnancy, and 1998 Munn et al revealed IDO 
activity to be critical for the induction of maternal 
immunotolerance. Subsequent studies were able to 
substantiate the central role of IDO activation in the 
development of immunodeficiency and immunotoler-
ance. Thereby IDO expression in DC is crucial in the 
control of regulatory T-cells.
Degradation  of  tryptophan  in  cancer  patients 
suggests that IDO activity may be involved in several 
typical symptoms of chronic inflammatory conditions. 
IDO is also related to impaired quality of life, and this 
correlation is obviously due to the close association 
between tryptophan and the biosynthesis of neurotrans-
mitter  serotonin.  Therefore,  tryptophan  deficiency 
could represent an important aspect in the pathogene-
sis of cognitive impairment and depression in patients 
with immunopathologic clinical conditions.
Data  on  IDO  thereby  provide  a  basis  to  better 
understand the complex interplay between immune 
activation cascades and the development of immuno-
deficiency, or in other words, of the pro- and anti-
inflammatory consequences of IFN-γ, among which 
IDO  is  a  central  component.  IFN-γ-induced  IDO 
activity during malignant tumor diseases is part of 
the  physiologic  tumoricidal  immune  defense  strat-
egy, which in the long run might be detrimental to 
the host, when tryptophan deprivation and production 
of pro-apoptotic tryptophan catabolites, counteracts 
T-cell responsiveness.
We  are  only  beginning  to  understand  the  com-
plexity of pathophysiological cascades in the tumor 
microenvironment,  where  particular  immune  cells 
play important roles in terms of tumor development 
and  progression. The Th1-type  cytokine  IFN-γ  has 
been shown to be crucial in this process via serving 
as a stimulus for anti-proliferative biochemical path-
ways. These include the kynurenine pathway in which 
the immunomodulatory enzyme IDO and its recently 
discovered relative IDO2 initiate the first step in the 
degradation of the essential amino acid L-tryptophan 
to ultimately form a plethora of immunomodulatory 
metabolites. Encoded by the INDO gene at human 
chromosome 8p12, IDO is an isoenzyme of hepatic 
tryptophan  2,3-dioxygenase  (tryptophan  pyrrolase, 
TDO) which was first described and isolated in 1963.1,2 
Over decades it has been reported that IDO plays an 
immunosuppressive role in a variety of chronic infec-
tions,  including  viral,  parasitic  and  bacterial  infec-
tions such as human immunodeficiency virus (HIV), 
malaria,  hepatitis  C,  Toxoplasma  gondii  and  Chla-
mydia.1–3 IDO is widely expressed in human tissues 
and cell subsets and its immunoregulatory properties 
have been shown to play a dominant role in immune 
responses and regulation towards self and foreign anti-
gens. A better understanding of these mechanisms will 
not only allow us to unveil the pathogenesis of many 
diseases but also discover new therapeutic approaches Tryptophan degradation in malignant tumor disease
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in terms of prevailing tumor escape and inducing 
immune tolerance.4 Maternal tolerance towards the 
semi-allogeneic fetus is only one example in which 
IDO has been shown to mediate immune privilege 
by preventing T-cell driven rejection.5 This ground-
breaking discovery paved the way for further research 
addressing  the  immunoregulatory  potential  of  IDO 
including a series of studies focusing on the role of 
IDO-mediated tryptophan metabolites in the immune 
escape of tumors.6 This review highlights the experi-
mental and clinical findings of IDO-induced trypto-
phan  degradation  in  the  pathogenesis  of  malignant 
tumor  disease  and  discusses  potential  novel  anti 
cancer-therapeutic strategies by targeting IDO.
IDO Mediated Tryptophan Metabolism
The two intracellular enzymes IDO and TDO initiate 
the rate limiting step in L-tryptophan degradation 
along the kynurenine pathway and ultimately form 
immunomodulatory  metabolites  like  L-kynurenine, 
3-hydroxykynurenine,  3-Hydroxyanthranilic  acid 
and picolinic acid. In case the immune system gets 
activated, high amounts of IFN-γ are released mainly 
by leukocytes. This results in sustained IDO activation 
most prominently in antigen presenting cells (APCs) 
like DCs, which leads to the afore-mentioned accu-
mulation of downstream tryptophan products. Besides 
that, a small amount of tryptophan is used for mela-
tonin synthesis in the pineal gland or metabolized to 
serotonin in the nervous system. Leucocytes are fur-
thermore the cell source to produce redox active com-
pounds like superoxide (OH*), which generates Fe2+ 
from Fe3+ within the heme-prosthetic group of IDO 
allowing it to proceed tryptophan metabolism (Fig. 1). 
This mechanism suggests that IDO activity is restricted 
to sites of infection or inflammation.7–9 Furthermore the 
redox potential of the microenvironment seems to influ-
ence the function of tryptophan metabolites as well.9
Immunosuppressive effects of IDO
The exact mechanism, how IDO acts immunosup-
pressive, is still under debate. Two main theories have 
Figure 1. The developing malignant process is recognized by immunocompetent cells and a broad response of several immunocompartments is mounted 
against the foreign surface structures of tumor cells. Among the immunoregulatory cytokines released during innate and adaptive immune responses, 
Th1-type cytokine interferon-γ (IFN-γ) stimulates several antiproliferative and tumoricidal biochemical pathways such as the formation of reactive oxygen 
species (ROs) and the degradation of tryptophan by indoleamine 2,3-dioxygenase (IDO) in macrophages, dendritic cells and tumor cells. As one important 
consequence, tryptophan stravation and the formation of toxic effector molecules like kynurenine derivatives and anthranilate not only affect proliferation 
of target tumor cells but also of T-cells and their immunoresponsiveness.
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been proposed either involving tryptophan metabolites 
or starving cells of tryptophan. After IDO activation 
has been described through the course of successful 
pregnancy,10 in 1998 Munn and Mellor discovered 
that  IDO  expression  at  the  feto-maternal-interface 
was crucial to prevent fetal rejection in pregnant mice. 
Pharmacologic  enzyme  inhibition  with  1-methyl-
tryptophan (1-MT) resulted in T cell mediated rejec-
tion of allogeneic but non-syngeneic fetuses.5 This 
maternal tolerance concept was based on the theory 
that local tryptophan depletion would maintain preg-
nancies  through  suppression  of  T-cell  driven  fetal 
rejection.  Tryptophan  depletion  induces  cell  cycle 
arrest in lymphocytes11 ultimately driving these cells 
into apoptosis.12 This is mainly regulated through the 
amino acid sensitive general control non- depressible 2 
(GCN2) stress kinase pathway which becomes acti-
vated upon IDO-induced tryptophan degradation and 
production of uncharged tRNA in T cells.13 A trypto-
phan threshold in order to inhibit T cell proliferation 
could not been defined yet. Munn et al reported that 
tryptophan  concentrations  in  vitro  had  to  decrease 
below  0.5–1  µM  to  inhibit  T-cell  proliferation,11 
others report that even completely tryptophan free 
cell  culture  medium  could  not  sufficiently  inhibit 
T lymphocytes from growing.14 In humans, plasma 
tryptophan levels range between 50–100 µM. It is 
currently unclear to what extent tryptophan degrada-
tion and starvation accounts for IDO mediated immu-
nosuppression since minimum tryptophan threshold 
limit values have not been defined and probably can 
not be defined in vivo. In case of inflammation and 
tumor growth necrotic cells release their intracellu-
lar stocks and thereby supply an additional source 
of  tryptophan  to  the  particular  microenvironment. 
Furthermore, local decrease in tryptophan can eas-
ily be replaced through diffusion from surrounding 
tissues. Taken all of these afore mentioned results into 
consideration it is currently unclear to what extent 
tryptophan  starvation  accounts  for  IDO-mediated 
immunosuppression.
The tryptophan metabolite theory is nourished by 
the  fact  that  downstream  metabolites  of  tryptophan 
cause cell cycle arrest and apoptosis in lymphocytes.14–16 
Furthermore, they foster via to date largely unknown 
mechanisms the differentiation of naïve CD4+ T cells 
into T regulatory cells (Treg).17 However one study 
suggests that 3-hydroxyanthralinic acid directly blocks 
T  cell  antigen  receptor-triggered  nuclear  factor-κB 
(NF-κB) activation through kinase 3-phosphoinositide-
dependent protein kinase 1 (PDK1) signaling which ulti-
mately leads to activated type 2 T helper cell death.18
In summary, both theories are not necessarily mutu-
ally exclusive but rather a concerted contribution of 
both mechanisms might contribute to IDO-mediated 
immune suppression in vivo.
Tumor Immunity Through IDO 
Mediated Tryptophan catabolism
Immune  escape  is  a  fundamental  trait  of  cancer.19 
A  variety  of  tumor  escape  mechanisms  have  been 
elucidated over the past.6,20 Key players in this cru-
cial  escape  mechanism  are  Tregs  and  regulatory 
DCs, which create tolerance to the antigen they are 
presenting. Furthermore, IDO also seems to play a 
detrimental role in tumor immunity by acting in a for-
ward feedback loop to instruct naïve CD4+ T cells to 
become Tregs but also by mediating Tregs to drive 
naive DCs into a regulatory status.21,22 By provoking 
a cycle of antigen tolerance IDO might switch the 
tumor microenvironment from hostile to supportive 
for tumor cells and also initiate a peripheral immune 
escape  mechanism  that  facilitates  progression  to 
a more invasive tumor status.19 Supporting the fact 
that IDO has a fundamental role in immune control, 
recent evidence suggests that the immunosuppressive 
drug dexamethasone operates upon IDO induction in 
DCs by reverse signaling through the glucocorticoid 
induced B7 inhibitory T cell co-receptor.23 IDO does 
not seem to be involved in tolerizing self-antigens 
but  rather  in  creating  a  tolerant  state  for  non-self 
antigens  (e.g.  fetal  antigens)  where  immune  non-
responsiveness is important.24 However in the even-
tuality of cancer, immune unresponsiveness to tumor 
antigens results in disease aggravation.
In  addition, T  cells  also  appear  to  be  predomi-
nantly sensitive to IDO activation, since upon tryp-
tophan starvation they cannot proliferate and become 
activated by means of antigen presentation and they 
rather translate into an anergic state. Tryptophan star-
vation furthermore triggers a Gcn2-dependent stress-
signaling pathway that ultimately leads to cell growth 
arrest through phosphorylation and translational ini-
tiation at the ribosome.13 Furthermore T cells seem to 
be preferentially vulnerable to kynurenine derivatives 
and other catabolites generated by the IDO pathway25 Tryptophan degradation in malignant tumor disease
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which  along  with  tryptophan  restriction  appears 
to be important for induction of Tregs and immune 
suppression.22,26
Clinical Significance of IDO 
expression in Human Malignancies
IDO expression can be detected in most human can-
cers including prostate, colorectal, pancreatic, cervical, 
endometrial, gastric, lung, bladder, ovarian, esopha-
geal and renal cell carcinomas, glioblastomas, meso-
theliomas, and melanomas.27–33 Clinical studies stress 
that high IDO expression of tumor cells correlates with 
outcome (Table 1). In endometrial cancer, ovarian can-
cer and high-grade osteosarcomas, respectively, IDO 
expression correlates with poor overall survival.34–36 
Furthermore, our own group was able to show that 
IDO had a significant prognostic value in terms of 
liver metastasis in patients with colorectal cancer. IDO 
expression goes along with reduced CD3+ lymphocyte 
infiltration suggesting a suppressive function on tumor 
reactive T-cells.37 In patients with hepatocellular carci-
noma similar findings were reported.38 Furthermore a 
significant relationship was found between the amount 
of IDO positive tumor infiltrating cells and overall sur-
vival in non small cell lung cancer.39 In addition the 
presence of metastatic infiltrating IDO positive cells 
into  the  lymph  node  at  initial  diagnosis  correlated 
with a significantly worse clinical outcome in malig-
nant lymphoma.40 In contrast IDO expression in tumor 
endothelial cells in patients with renal cell carcinoma 
correlates with long-term survival.41 Apart from IDO, 
pyrazinopyrimidine  compound  neopterin  has  been 
shown to be a reliable prognostic marker for human 
malignancies.42 Neopterin is released as an inflamma-
tory marker in large amounts from human monocyte-
derived macrophages and DCs preferentially following 
stimulation with the pro-inflammatory cytokine IFN-γ, 
thus reflecting the immune activation status. Increased 
neopterin  levels  in  patients  with  melanomas,  breast 
cancers,  squameous  cell  carcinomas,  gynecological 
tumors, and colorectal carcinomas have been shown to 
go along with poor prognostic outcomes.32,43–46
Since IFN-γ is one of the strongest inducers of 
IDO expression47 and due to its sustained effects on 
tumor cell proliferation the cross-linked interplay of 
IFN-γ and IDO seems to be of great importance. This 
hypothesis is additionally supported by in vivo studies 
in an ovarian carcinoma mouse model where IL-12, 
a cytokine with anti-tumor activity, induced complete 
regression of fibrosarcomas and ovarial carcinomas 
due to IFN-γ induced IDO activity.48
Besides its anti-proliferative effects on transformed 
cells49 IFN-γ seems to exert even stronger inhibitory 
effects on human cancer cell proliferation upon IDO 
expression. Almost two decades ago it has been shown 
in vitro that IFN-γ induced IDO expression leads to 
tryptophan degradation in cell culture medium result-
ing in cell proliferation arrest. However tryptophan 
supplementation of growth medium reversed the anti-
proliferative effects of IFN-γ.50
Table 1.
Tumor entity Overall survival of  
patients with increased  
IDO expression
progression-free survival  
of patients with increased  
IDO expression
References
Malignant melanoma Reduced Reduced 31,32
Acute myeloid leukemia Reduced Reduced 33
Ovarian serous carcinoma Reduced Not evaluated 34
Ovarian clear cell carcinoma No correlation Not evaluated 34
endometrial carcinoma Reduced Reduced 35
Osteosarcoma Reduced Reduced 36
colorectal carcinoma No correlation Not evaluated 37
Hepatocellular carcinoma Not evaluated prolonged 38
Renal cell carcinoma prolonged Not evaluated 41
esophageal squammous  
cell carcinoma
Not evaluated Not evaluated 29
Lung cancer Not evaluated Not evaluated 30sucher et al
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In  conclusion,  IDO  induction  seems  to  be  one 
mechanism by which IFN-γ inhibits malignant cell 
outgrow  thereby  being  a  decisive  mechanism  of 
tumor attack.
IDO Inhibition, a potential Mechanism 
of cancer Therapy in the Future?
Since IDO plays a major role in the escape of malig-
nant cells from immunological attack it is obvious that 
blocking its activity should increase the anti-tumoral 
response and halt tumor progression. In vitro stud-
ies showed that 1-MT treatment delayed outgrowth 
of mouse melanoma cells that have been engrafted 
into syngeneic hosts.51 Furthermore over-expression 
of IDO promotes tumor growth, which again could 
be partially reversed by pharmacologic inhibition.28 
However, in a murine breast cancer model it has been 
shown recently that 1-MT, although present in suf-
ficient concentrations, only slightly retarded autoch-
thonous breast cancer. Because 1-MT only seems to 
be able to slow down and not to prevent tumor growth 
it was combined with several chemotherapeutic drugs 
or radiotherapy resulting in even more pronounced 
anti-tumoral  effects.52,53  The  molecular  mechanism 
by which IDO inhibition contributes to the benefi-
cial partnership with chemotherapy still remains to 
be elucidated. 1-MT exists in two isoforms, L-1-MT 
and D-1-MT which both inhibit IDO and its relative 
IDO2,  respectively.  In  subsequent  murine  tumor 
models it turned out that only D-1-MT significantly 
prolonged survival when combined with conventional 
chemotherapeutics.53  However,  IDO  has  a  tenfold 
higher affinity for the L-isomer than the D-isomer, 
indicating that D-1-MT is less efficient in blocking 
IDO  enzymatic  activity.  Interestingly  D-1-MT  did 
not block IFN-γ treated tumor cell lines or IDO trans-
fected cell lines.53 However, in some other experi-
ments it was able to block tryptophan degradation 
of IDO expressing DCs that were used as stimula-
tor cells in allogeneic mixed lymphocyte culture and 
accordingly increased T-cell proliferation in the co 
culture system. The question why D-1-MT inhibits 
IDO activity in only some cells and does not inhibit 
the activity of the purified IDO enzyme was answered 
when another IDO isoform was discovered. The gene 
IDO2 encodes an IDO-like protein and has recently 
been detected on the human chromosome 8. IDO2 
is inhibited by D-1-MT but unaffected by L-1-MT54 
and is constitutively expressed in several tissues.55 
When  compared  to  IDO,  IDO2  has  only  3%–5% 
of enzymatic activity, however this activity can be 
increased  through  modified  assay  conditions.4,55 
Although D-1-MT has recently entered clinical trials 
(NCT00567931; New link genetics corporation; Pat-
ent Storm) therapeutic effects in humans still have to 
be figured out. Current data have revealed that only 
the Levo-isoform of 1-MT has IDO blocking capaci-
ties in human malignancies where only IDO but not 
IDO2  is  expressedv.56  Furthermore,  even  if  IDO2 
would be active, only a subset of patients would ben-
efit from therapy with D-1-MT as 50% of Caucasians 
lack functional IDO2 alleles.4,54
conclusion
Summarizing  the  experimental  and  clinical  data 
above, there is clear evidence that IDO interferes with 
immune regulation. IDO has evolved from a simple 
tryptophan  catabolizing  enzyme  into  an  important 
immune regulator and an important player in tumor 
immunosurveillance. There is a great body of evi-
dence that IDO is expressed by tumor cells, tumor 
infiltrating immune cells and in tumor draining lymph 
nodes and that the expression of IDO contributes to 
the ability of tumors to evade the immune system. 
Taken together these facts offer a rationale for the 
clinical investigation of the capacity of IDO inhibi-
tors to increase the efficacy of anticancer immuno-
therapy, in addition to conventional tumor radiation 
and chemotherapeutic agents. In particular, combin-
ing chemotherapy with pharmacologic IDO inhibi-
tion seems to be key to success in preventing IDO 
mediated immunologic tolerance when chemotherapy 
has already destroyed tumor cells and released tumor 
antigens.
Studying  IFN-γ-induced  IDO  activity  in  tumors 
may also lead to a better general understanding of 
immunoregulation in cancer and foster novel thera-
peutic strategies for modern cancer warfare.
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